This case was originally captioned as Alliance for Hippocratic Medicine et al. v. Food and Drug Administration et al. Following review by the Supreme Court, the private plaintiffs dismissed their claims. This left Missouri, Kansas, and Idaho as the sole remaining plaintiffs. The case was then transferred from the Northern District of Texas to the Eastern District of Missouri where the litigation will proceed. For previous district court filings, please see the Northern District of Texas case page here.
- Docket No.
- 4:25-cv-01580
- District Court
- Missouri Eastern
Goal
- Block enforcement of an agency action
- Declaration that agency action is unlawful
Issues
Case History
Litigation Content
Why this Matters
The states allege that the Food and Drug Administration’s (FDA) approval and regulation of mifepristone as safe and effective violates the Administrative Procedure Act; the Food, Drug, and Cosmetic Act; and the Comstock Act, and is ultra vires. Ensuring access to FDA-approved medication abortion enables patients to receive reproductive health care.
Potential Impact
Preventing women from accessing effective medication for abortion services will jeopardize their health and safety. Additionally, preventing the FDA from making clinical and scientific determinations will endanger the agency’s ability to ensure individuals have access to safe and effective drugs.